LOGIN  |  REGISTER

Latest Medical Device News

NeuroPace to Present at the 44th Annual J.P. Morgan Healthcare Conference

December 31
Last Trade: 15.39 -0.08 -0.52

MOUNTAIN VIEW, Calif. / Dec 31, 2025 / Business Wire / NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today announced that its management team will present at the 44th Annual J.P. Morgan Healthcare Conference at 3:00pm PT on Wednesday, January 14, 2026, in San Francisco, CA. Management will also host investor meetings during the conference. The presentation will be...Read more


Intelligent Bio Solutions Announces New Manufacturing Partnership to Strengthen Global Production Capability and Increase Margins

December 31
Last Trade: 8.34 4.24 103.41

Partnership with Syrma Johari Medtech, a globally recognized medical device engineering and manufacturing organization, expands INBS’ global manufacturing capacity, strengthens supply-chain resilience, and supports an expected improvement of approximately 20 percentage points in gross margin ahead of planned U.S. market entry NEW YORK, Dec. 31, 2025 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) ("INBS" or the...Read more


ICU Medical to Present at the 44th Annual J.P. Morgan Healthcare Conference

December 31
Last Trade: 143.59 -1.04 -0.72

SAN CLEMENTE, Calif., Dec. 31, 2025 (GLOBE NEWSWIRE) -- ICU Medical, Inc. (Nasdaq: ICUI), a leader in the development, manufacture and sale of innovative medical products, today announced that Company management will present at the 44th Annual J.P. Morgan Healthcare Conference being held in San Francisco, California, January 12-15, 2026. ICU Medical’s presentation will be on Wednesday, January 14, 2026 at 1:30 p.m. PT (4:30 p.m. ET)....Read more


Establishment Labs to Present at 44th Annual J.P. Morgan Healthcare Conference

December 31
Last Trade: 74.48 1.56 2.14

NEW YORK / Dec 31, 2025 / Business Wire / Establishment Labs Holdings Inc. (NASDAQ: ESTA), a global medical technology company dedicated to improving women’s health and wellness, principally in breast aesthetics and reconstruction, today announced that Peter Caldini, Chief Executive Officer, and Raj Denhoy, Chief Financial Officer, will present at the 44th Annual J.P Morgan Healthcare Conference on January 14, 2026 at 9:45 a.m. PT. A live...Read more


Delcath Systems Announces Publication of Subgroup Analyses of the Phase 3 FOCUS Study of Melphalan/Hepatic Delivery System in Patients with Unresectable Metastatic Uveal Melanoma

December 31
Last Trade: 10.12 -0.03 -0.30

QUEENSBURY, N.Y. / Dec 31, 2025 / Business Wire / Delcath Systems, Inc. (Nasdaq: DCTH), (“Delcath” or the “Company”) an interventional oncology company focused on the treatment of primary and metastatic liver cancers, today announced the publication of results from subgroup analyses of the phase 3 FOCUS study. The publication, titled “Subgroup Analyses of the Phase 3 FOCUS Study of Melphalan/Hepatic Delivery System in Patients with...Read more


Alcon to Present at 2026 Annual J.P. Morgan Healthcare Conference

December 30
Last Trade: 78.92 -0.39 -0.49

GENEVA / Dec 30, 2025 / Business Wire / Alcon (SIX/NYSE: ALC) CEO David Endicott will present at the 2026 J.P. Morgan Healthcare Conference on Tuesday, January 13, 2026, at 8:15 a.m. PST. A live webcast of the conference will be available at investor.alcon.com/news-and-events/events-and-presentations. About Alcon Alcon helps people see brilliantly. As the global leader in eye care with a heritage spanning over 75 years, we offer the...Read more


KORU Medical Systems Announces 510(k) Submission for Clearance of the FreedomEDGE® System with a Commercialized Oncology Biologic

December 30
Last Trade: 5.85 0.16 2.81

MAHWAH, N.J. / Dec 30, 2025 / Business Wire / KORU Medical Systems, Inc. (NASDAQ: KRMD) (“KORU Medical” or the “Company”), a leading medical technology company focused on the development, manufacturing, and commercialization of innovative and patient-centric large volume subcutaneous infusion solutions, today announced the submission of a 510(k) premarket notification to the U.S. Food and Drug Administration (FDA) seeking clearance for the...Read more


Treace Medical Concepts to Present at 44th Annual J.P. Morgan Healthcare Conference

December 30
Last Trade: 2.46 -0.02 -0.69

PONTE VEDRA, Fla., Dec. 30, 2025 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace” or the “Company”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities, today announced that John T. Treace, Chief Executive Officer, will present at the 44th Annual J.P. Morgan Healthcare Conference on Wednesday, January 14, 2026, beginning at approximately...Read more


Autonomix Medical Granted European Patent on Platform Technology Enabling Precision Nerve-Targeted Therapies in Cardiology

December 30
Last Trade: 0.52 -0.06 -11.03

With over 80 issued patents and 39 pending patent applications, Autonomix is building a comprehensive, global IP portfolio in nerve-sensing and modulation Newly granted patent further strengthens the Company’s strategic position in a multi-billion-dollar market opportunity, unlocking potential across cardiovascular, renal, and other high-burden diseases THE WOODLANDS, TX, Dec. 30, 2025 (GLOBE NEWSWIRE) -- Autonomix Medical,...Read more


Kestra Medical Technologies to Present at the 44th Annual J.P. Morgan Healthcare Conference

December 30
Last Trade: 0 0.00 0.00

KIRKLAND, Wash., Dec. 30, 2025 (GLOBE NEWSWIRE) -- Kestra Medical Technologies, Ltd. (Nasdaq: KMTS), a wearable medical device and digital healthcare company, is scheduled to present at the 44th Annual J.P. Morgan Healthcare Conference on Tuesday, January 13 at 2:15 p.m. Pacific Time. Interested parties may access the live webcast and replay of the presentation by visiting the Kestra Medical Technologies investor relations...Read more


Profound Medical Announces Closing of Private Placement

December 30
Last Trade: 7.24 -0.21 -2.82

TORONTO, Dec. 30, 2025 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”) is pleased to announce that it has completed its previously announced private placement of common shares to Canadian investors (the “Offering”). Pursuant to the Offering, the Company issued an aggregate of 921,428 common shares at a price of US$7.00 per common share, for aggregate gross proceeds of approximately US$6.45...Read more


INVO Fertility Aligns Executive Leadership Structure to Support Growth Strategy

December 30
Last Trade: 2.04 0.00 0.00

Terah Krigsvold to replace Andrea Goren as CFO, who is named chief business officer and CEO of INVO Centers LLC to focus on growth efforts SARASOTA, Fla., Dec. 30, 2025 (GLOBE NEWSWIRE) -- INVO Fertility, Inc. (Nasdaq: IVF) (“INVO” or the “Company”), a healthcare fertility company focused on the establishment, acquisition, and operation of fertility clinics and related businesses and technologies, today announced changes to its...Read more


Picard Medical CEO Patrick NJ Schnegelsberg Elected to AZBio Board of Directors

December 30
Last Trade: 0 0.00 0.00

TUCSON, Ariz., Dec. 30, 2025 (GLOBE NEWSWIRE) -- Picard Medical, Inc. (NYSE American: PMI) (“Picard” or the “Company”), parent company of SynCardia Systems, LLC, maker of the world’s first total artificial heart approved by both the U.S. Food and Drug Administration (FDA) and Health Canada today announced that Patrick NJ Schnegelsberg, Chief Executive Officer of Picard Medical and SynCardia Systems, LLC, has been elected to the Board of...Read more


Penumbra to Present at the 44th Annual J.P. Morgan Healthcare Conference

December 29
Last Trade: 314.63 0.36 0.11

ALAMEDA, Calif., Dec. 29, 2025 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN) today announced that its management team is scheduled to present at the 44th Annual J.P. Morgan Healthcare Conference on Monday, January 12, 2026. Event:  44th Annual J.P. Morgan Healthcare Conference Date:  Monday, January 12, 2026 Time:  6:45pm ET/3:45pm PT A webcast of the presentation can...Read more


iRhythm Technologies to Present at the 44th Annual J.P. Morgan Healthcare Conference

December 29
Last Trade: 178.85 0.28 0.16

SAN FRANCISCO, Dec. 29, 2025 (GLOBE NEWSWIRE) -- iRhythm Technologies, Inc. (NASDAQ:IRTC), a leading digital health care company focused on creating trusted solutions that detect, predict, and prevent disease, announced today that the company will be participating in the upcoming 44th Annual J.P. Morgan Healthcare Conference. iRhythm’s management is scheduled to present on Monday, January 12, 2026, at 8:15 a.m. Pacific Time / 11:15 a.m....Read more


CooperCompanies to Present at the J.P. Morgan Healthcare Conference

December 29
Last Trade: 81.98 -0.49 -0.59

SAN RAMON, Calif., Dec. 29, 2025 (GLOBE NEWSWIRE) -- CooperCompanies (Nasdaq: COO), a leading medical device company, announced today it will participate at the J.P. Morgan Healthcare Conference on Wednesday, January 14, 2026. Al White, President and CEO, will represent the Company in a session scheduled to begin at 5:15pm ET. A live and archived webcast of the event, where applicable, will be available on the CooperCompanies’ website at...Read more


Pulse Biosciences to Present at the 44th Annual J.P. Morgan Healthcare Conference

December 29
Last Trade: 13.75 0.00 0.00

HAYWARD, Calif. / Dec 29, 2025 / Business Wire / Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel nPulse™ technology using its proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™) energy, today announced plans to present at the upcoming 44th Annual J.P. Morgan 2026 Healthcare Conference in San Francisco. Pulse Biosciences’ Management is scheduled to present on Wednesday, January 14, 2026, at 3:45pm...Read more


Nyxoah to Present at the 44th Annual J.P. Morgan Healthcare Conference

December 29
Last Trade: 4.70 0.05 1.08

Nyxoah to Present at the 44th Annual J.P. Morgan Healthcare Conference Mont-Saint-Guibert, Belgium – December 29, 2025, 10:05pm CET / 4:05pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology company that develops breakthrough treatment alternatives for Obstructive Sleep Apnea (OSA) through neuromodulation, today announced that the management team will present at the 44th Annual J.P....Read more


CapsoVision Announces 510(k) Submission for the Addition of AI-Assisted Reading Module in CapsoCam Plus®

December 29
Last Trade: 0 0.00 0.00

Company Preparing to Commence Commercialization Following U.S. FDA 510(k) Clearance SARATOGA, Calif., Dec. 29, 2025 (GLOBE NEWSWIRE) -- CapsoVision, Inc. (NASDAQ: CV), a commercial-stage medical technology company developing advanced imaging and AI-enabled capsule endoscopy solutions, today announced submission of its 510(k) application to the Food and Drug Administration (FDA) for its proprietary AI-assisted module for CapsoCam...Read more


WORK Medical Technology Grants East China Exclusive Distribution Rights for AI-Automated Blood Cell Morphology Analyzer, Sets RMB10 Million Sales Target for 2026

December 29
Last Trade: 2.48 -0.46 -15.65

Hangzhou, China, Dec. 29, 2025 (GLOBE NEWSWIRE) -- WORK Medical Technology Group LTD (Nasdaq: WOK) (“WORK Medical”, the “Company” or “we”), a supplier of medical devices in China, through its subsidiary, Work (Hangzhou) Medical Treatment Equipment Co., Ltd. and its subsidiaries in China, today announced that its subsidiary, Hunan Saitumofei Medical Treatment Technology Co., Ltd. (“Hunan Saitumofei”) has entered into a one-year exclusive...Read more


WORK Medical Technology Subsidiary Obtains Manufacturing Approval for Its AI-Automated Blood Cell Morphology Analyzer

December 29
Last Trade: 2.48 -0.46 -15.65

Hangzhou, China, Dec. 29, 2025 (GLOBE NEWSWIRE) -- WORK Medical Technology Group LTD (Nasdaq: WOK) (“WORK Medical” or the “Company”), a supplier of medical devices in China, through its subsidiary, Work (Hangzhou) Medical Treatment Equipment Co., Ltd. and its subsidiaries in China, today announced that its subsidiary, Hunan Saitumofei Co., Ltd., has received manufacturing approval from the Hunan Provincial Medical Products Administration...Read more


Establishment Labs Submits to FDA for Approval of Motiva Implants in Breast Reconstruction

December 29
Last Trade: 74.48 1.56 2.14

NEW YORK / Dec 29, 2025 / Business Wire / Establishment Labs Holdings Inc. (NASDAQ: ESTA), a global medical technology company dedicated to improving women’s health and wellness, principally in breast aesthetics and reconstruction, today announced that it has submitted Motiva® implants for approval in primary and revision breast reconstruction to the U.S. Food and Drug Administration (FDA). The products were previously approved by the FDA...Read more


Inspire Medical Systems to Present at the 44th Annual J.P. Morgan Healthcare Conference

December 29
Last Trade: 92.07 -0.50 -0.54

MINNEAPOLIS, Dec. 29, 2025 (GLOBE NEWSWIRE) -- Inspire Medical Systems, Inc. (NYSE: INSP) (Inspire), a medical technology company focused on the development and commercialization of innovative, minimally invasive solutions for patients with obstructive sleep apnea, announced today that its management team will present at the 44th Annual J.P. Morgan Healthcare Conference on Monday, January 12, 2026. Inspire is scheduled to present at...Read more


Bluejay Diagnostics Announces Completion of Commercial-Scale IL-6 Antibody Production

December 29
Last Trade: 0.70 -0.03 -4.26

ACTON, Mass., Dec. 29, 2025 (GLOBE NEWSWIRE) -- Bluejay Diagnostics, Inc. (NASDAQ: BJDX) (“Bluejay” or the “Company”) announced that it has completed commercial-scale production of both polyclonal and monoclonal antibodies targeting interleukin-6 (IL-6), a biomarker relevant to inflammatory and critical-care applications. The Company stated that both polyclonal and monoclonal antibodies met internal performance criteria, including...Read more


QHSLab Completes $500K Private Placement, Enters 2026 With Clean Capital Structure

December 29
Last Trade: 0.55 0.00 0.00

With legacy overhang removed and new capital secured, management shifts focus from balance-sheet repair to disciplined growth execution. West Palm Beach, FL, Dec. 29, 2025 (GLOBE NEWSWIRE) -- QHSLab Inc. (the “Company”) (OTCQB: USAQ), a healthcare technology company focused on digital medicine and population health innovation, today announced the completion of a $500,000 private placement with accredited investors, providing fresh...Read more


Conavi Medical Reports Fiscal Year 2025 Results and Operational Highlights

December 29
Last Trade: 0.46 0.00 0.00

Next-Generation Novasight Hybrid™ System Submitted to U.S. FDA for 510(k) Clearance U.S. and European Class 1A Guidelines Reinforce Growing Adoption of Image-Guided PCI Peer-Reviewed Publications Highlight Clinical Importance of Intravascular Imaging Leadership Team Expanded to Support U.S. Commercial Launch and Operational Scale-Up Company Advances Manufacturing, Conference Visibility, and Launch Readiness TORONTO, Dec. 29, 2025...Read more


Picard Medical Announces Up to $50 Million Senior Secured Debt Financing

December 24
Last Trade: 0 0.00 0.00

TUCSON, Ariz., Dec. 24, 2025 (GLOBE NEWSWIRE) -- Picard Medical, Inc. (NYSE American: PMI) (“Picard” or the “Company”), parent company of SynCardia Systems LLC, maker of the world’s first total artificial heart approved by both the U.S. FDA and Health Canada, today announced that it has entered into a definitive agreement for a private placement financing of up to $50.0 million aggregate principal amount of senior secured notes due 2028...Read more


FDA Approves Edwards Lifesciences' SAPIEN M3 Mitral Valve Replacement System as First Transseptal Transcatheter Therapy

December 23
Last Trade: 86.01 -0.20 -0.23

IRVINE, Calif. / Dec 23, 2025 / Business Wire / Edwards Lifesciences (NYSE: EW) today announced the company’s SAPIEN M3 mitral valve replacement system is the first transcatheter therapy utilizing a transseptal approach to receive U.S. Food and Drug Administration (FDA) approval for the treatment of mitral regurgitation (MR). The SAPIEN M3 transcatheter mitral valve replacement (TMVR) system is indicated for the treatment of symptomatic...Read more


LivaNova to Present at J.P. Morgan Healthcare Conference in January

December 23
Last Trade: 61.78 -0.45 -0.72

LONDON / Dec 23, 2025 / Business Wire / LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today announced it will present at the J.P. Morgan 44th Annual Healthcare Conference in San Francisco. Vladimir Makatsaria, Chief Executive Officer of LivaNova, and Alex Shvartsburg, Chief Financial Officer, will participate in a fireside chat on Wed., Jan. 14, 2026, at 1:30 p.m. Pacific Standard Time. The discussion will be...Read more


Bone Biologics Improves Extension of rhNELL-1 Product Shelf Life to 24 Months

December 23
Last Trade: 1.58 0.06 3.75

Milestone advances manufacturing readiness and supports long-term commercialization strategy BURLINGTON, Mass., Dec. 23, 2025 (GLOBE NEWSWIRE) -- Bone Biologics Corporation ("Bone Biologics" or the "Company") (NASDAQ: BBLG, BBLGW), a developer of orthobiologic products for spine fusion markets, announces it has received confirmation that the shelf life of its rhNELL-1 product has been extended to 24 months, delivering on previously...Read more


Profound Medical Closes $36 Million Registered Direct Offering; Expects to Complete Subsequent Private Placement On or Before December 30th

December 23
Last Trade: 7.24 -0.21 -2.82

Financing included participation by healthcare-dedicated investors alongside existing shareholders TORONTO, Dec. 23, 2025 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”) today announced the closing of its previously announced registered direct offering of 5,142,870 common shares at a purchase price of $7.00 per share, for gross proceeds of approximately $36 million before fees and...Read more


Theralase Technologies Closes $1.3 M Non-Brokered Private Placement

December 23
Last Trade: 0.16 0.00 0.00

Toronto, Ontario--(Newsfile Corp. - December 23, 2025) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a clinical stage pharmaceutical company pioneering light, radiation, sound and drug-activated therapeutics for the treatment of cancer, bacteria and viruses is pleased to announce that it has successfully closed a non-brokered private placement offering ("Offering") of units...Read more


Nanalysis Scientific Announces Upsize to Private Placement and Closing of the First Tranche

December 23
Last Trade: 0.17 0.00 0.00

CALGARY, AB, Dec. 23, 2025 /CNW/ - Nanalysis Scientific Corp. (the "Company" or "Nanalysis") (TSXV: NSCI, OTCQX: NSCIF, FRA: 1N1) is pleased to announce that it has closed the first tranche of its previously announced non-brokered private placement of units (the "Offering"), issuing an aggregate of 16,526,283 units of the Company (the "Units") at a price of $0.15 per Unit for gross proceeds of approximately $2.5 million. The net...Read more


CooperCompanies Appoints Walter M Rosebrough, Jr. to its Board of Directors

December 23
Last Trade: 81.98 -0.49 -0.59

Enters into Cooperation Agreement with Browning West SAN RAMON, Calif., Dec. 23, 2025 (GLOBE NEWSWIRE) -- CooperCompanies (Nasdaq: COO), a leading medical device company, announced today that the Company’s Board of Directors (the “Board”) has appointed Walter (Walt) M Rosebrough, Jr. as an independent director, effective as of January 3, 2026. In connection with this appointment, the Company also has entered into a cooperation...Read more


Vivos Inc Summarizes Progress in its Animal Therapy Division

December 22
Last Trade: 0.06 0.00 0.00

Kennewick, WA, Dec. 22, 2025 (GLOBE NEWSWIRE) -- Vivos Inc. (OTCQB: RDGL) The IsoPet division reported a 1,200% year-over-year increase in administered therapies from 2024 to 2025, reflecting accelerating veterinary adoption nationwide. In recent months, the Company has seen a sharp rise in inbound inquiries from both veterinarians and pet owners seeking access to IsoPet therapy, signaling growing awareness and demand for this precise,...Read more


MIMEDX Enters into Exclusive U.S. Distribution Agreement for RegenKit®-Wound Gel

December 22
Last Trade: 6.85 -0.01 -0.15

Company Continues to Broaden Leading Wound Product Offering MARIETTA, Ga., Dec. 22, 2025 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today announced it has entered into an exclusive agreement with Regen Lab USA LLC to distribute their RegenKit®-Wound Gel in the United States. RegenKit®-Wound Gel is an autologous platelet-rich plasma (PRP) and autologous thrombin serum (ATS) wound gel that removes...Read more


Abbott's Volt Pulsed Field Ablation System Receives FDA Approval to Treat Patients with Atrial Fibrillation

December 22
Last Trade: 125.58 -0.20 -0.16

Abbott's Volt™ PFA System, the latest generation of cardiac ablation technology, is designed for people battling heart rhythm disorders such as atrial fibrillation (AFib) Pulsed field ablation – or PFA – is a minimally invasive procedure that uses high-energy electrical pulses in targeted areas of the heart to treat irregular heart rhythms Abbott's Volt PFA System is an all-in-one product that is clinically proven to simplify the...Read more


CVRx to Present at the 44th Annual J.P. Morgan Healthcare Conference

December 22
Last Trade: 7.24 0.06 0.84

MINNEAPOLIS, Dec. 22, 2025 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) ("CVRx"), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases, today announced that the management team will present at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco on Wednesday, Jan. 14, 2026. The Company's presentation...Read more


AngioDynamics to Present at the 44th Annual J.P. Morgan Healthcare Conference

December 22
Last Trade: 12.92 -0.09 -0.69

LATHAM, N.Y. / Dec 22, 2025 / Business Wire / AngioDynamics, Inc. (NASDAQ: ANGO), a medical technology company focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment options and improving patient quality of life, today announced, that Jim Clemmer, President and Chief Executive Officer, and Stephen Trowbridge, Executive Vice President and Chief Financial Officer, will present at the 44th Annual J.P....Read more


Zimmer Biomet to Present at the 44th Annual J.P. Morgan Healthcare Conference

December 22
Last Trade: 90.65 -0.14 -0.15

WARSAW, Ind., Dec. 22, 2025 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced that members of the Zimmer Biomet management team will be presenting at the 44th Annual J.P. Morgan Healthcare Conference on Tuesday, January 13, 2026, at 8:15 a.m. PT (11:15 a.m. ET). A live webcast of the presentation can be accessed via Zimmer Biomet's Investor Relations website at...Read more


Quanterix Announces Landmark Nature Study Redefining Alzheimer’s Disease Neuropathology Prevalence

December 22
Last Trade: 6.27 -0.07 -1.11

Simoa p-Tau 217 Assay Enables Largest Population-Based Assessment (11,000+ Samples) Revealing Striking Age-Related Increase and Broad Treatment Eligibility BILLERICA, Mass. / Dec 22, 2025 / Business Wire / Quanterix Corporation (NASDAQ: QTRX), a company transforming healthcare by accelerating biomarker breakthroughs from discovery to diagnostics, today announced publication of a landmark study in the prestigious journal Nature. The...Read more


BrainsWay Reports Expansion of Adolescent Depression Coverage Applicable to Deep TMS™

December 22
Last Trade: 19.05 0.07 0.37

Optum Behavioral Health, a Health Services Company with Over 48 Million Covered Lives, Joins Growing List of Insurers Now Covering Deep TMS Depression Therapy for Adolescents Aged 15 and Older BURLINGTON, Mass. and JERUSALEM, Dec. 22, 2025 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced noninvasive brain stimulation technologies, today announced that Optum...Read more


Novocure to Present at 44th Annual J.P. Morgan Healthcare Conference

December 22
Last Trade: 13.15 -0.08 -0.60

BAAR, Switzerland / Dec 22, 2025 / Business Wire / Novocure (NASDAQ: NVCR) announced today that management will participate in the 44th Annual J.P. Morgan Healthcare Conference taking place in San Francisco on January 12-15, 2026. Frank Leonard, Chief Executive Officer, will present on behalf of the company and address questions on Wednesday, January 14, at 9:45 a.m. PST. Mr. Leonard will be joined by William Doyle, Executive Chairman, and...Read more


Medtronic announces filing of IPO registration statement for Diabetes business, MiniMed

December 19
Last Trade: 96.49 -0.17 -0.18

GALWAY, Ireland, Dec. 19, 2025 /PRNewswire/ -- Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced that its Diabetes business, which as previously announced will operate under the name MiniMed, has filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission (SEC) for a proposed initial public offering (IPO) of newly issued common stock. The separation is expected to be...Read more


Lifeward Appoints Bob Marshall as Chairman of the Board

December 19
Last Trade: 0.58 0.02 2.69

MARLBOROUGH, Mass. and YOKNEAM ILLIT, Israel, Dec. 19, 2025 (GLOBE NEWSWIRE) -- Lifeward Ltd., (Nasdaq: LFWD) (“Lifeward” or the “Company”), a global leader in innovative medical technology designed to transform the lives of people with physical limitations or disabilities, announced today that its Board of Directors has appointed Bob Marshall as Chairman of the Board, effective January 1, 2026. He replaces Joseph Turk, who will...Read more


Pro-Dex Announces Contract Extension With Largest Customer

December 19
Last Trade: 38.09 -0.52 -1.35

IRVINE, CA / ACCESS Newswire / December 19, 2025 / PRO-DEX, INC. (NasdaqCM:PDEX) today announced that on December 17, 2025, it executed a contract amendment with its largest customer for an additional three years. The contract, which was scheduled to terminate on December 31, 2025, has now been extended through December 31, 2028. The contract also contains minimum purchase volumes for each of the 2026 and 2027 calendar years. "We are...Read more


MiMedx Announces Publication in the Journal of Inflammation Focused on Immunomodulatory Effects of Purion® Processed Human Amniotic Membrane Allografts In Vitro

December 19
Last Trade: 6.85 -0.01 -0.15

Study investigates the influence of MIMEDX DHACM and LHACM products on inflammatory response, which supports the healing cascade and tissue repair MARIETTA, Ga., Dec. 19, 2025 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today announced the latest addition to its industry-leading body of scientific and clinical evidence supporting the use of its dehydrated human amnion chorion membrane (DHACM) and...Read more


AVITA Medical to Present at the 44th Annual J.P. Morgan Healthcare Conference

December 18
Last Trade: 3.48 0.03 0.87

VALENCIA, Calif., Dec. 18, 2025 (GLOBE NEWSWIRE) -- AVITA Medical®, Inc. (ASX: AVH, NASDAQ: RCEL), a leading therapeutic acute wound care company delivering transformative solutions, today announced that Cary Vance, Chief Executive Officer, will present at the 44th Annual J.P. Morgan Healthcare Conference on Wednesday, January 14, 2026, at 5:15 p.m. Pacific Time. A live audio webcast of the presentation will be accessible under the...Read more


Femasys Secures U.S. FDA Clearance for Next-Generation FemVue Diagnostic Device

December 18
Last Trade: 0.56 -0.02 -2.62

-- Innovative single-device solution integrates proven FemVue and FemChec® technologies to support fallopian tube evaluation and improve workflow efficiency-- ATLANTA, Dec. 18, 2025 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a leading biomedical innovator making fertility and non-surgical permanent birth control more accessible and cost-effective to women worldwide, announced today it has received 510(k) clearance from the...Read more


Abbott's Amplatzer Piccolo™ Delivery System Receives FDA Clearance and CE Mark to Optimize Procedures for Premature Babies With a Hole in the Heart

December 18
Last Trade: 125.58 -0.20 -0.16

First and only delivery system designed specifically for premature infants with a patent ductus arteriosus (PDA), a life-threatening opening in their heart New delivery system enables precise placement of Abbott's Amplatzer Piccolo Occluder in the tiniest babies A PDA requiring treatment is present in approximately 20% of premature infants1 ABBOTT PARK, Ill., Dec. 18, 2025 /PRNewswire/ -- Abbott (NYSE: ABT) today announced it has...Read more


Tandem Diabetes Care t:slim Mobile App Now Available in Canada

December 18
Last Trade: 22.27 -0.24 -1.07

SAN DIEGO / Dec 18, 2025 / Business Wire / Tandem Diabetes Care, Inc. (Nasdaq: TNDM) a leading insulin delivery and diabetes technology company, today announced availability of the Tandem t:slim mobile application for Android and iOS users in Canada. The Tandem t:slim mobile app allows users to deliver a bolus from their compatible smartphone, and to wirelessly upload their pump data to the cloud-based Tandem Source platform.1 “With this...Read more


Owlet Announces New DME Partnership With 1 Natural Way to Expand Insurance-Supported Access to BabySat® Infant Pulse Oximeter

December 18
Last Trade: 16.18 0.15 0.94

Collaboration expands Owlet’s national DME footprint, strengthens access for Medicaid and TRICARE families, and supports continued growth in prescription-backed revenue channel. LEHI, Utah / Dec 18, 2025 / Business Wire / Owlet, Inc. (“Owlet” or the “Company”) (NYSE: OWLT), the pioneer of smart infant monitoring, today announced a new durable medical equipment (DME) partnership with 1 Natural Way, a leading national...Read more


Intelligent Bio Solutions Announces Strategic Partnership with Vlepis, Provider of Advanced Sensing and Wearable Patch Technologies, to Drive Innovation in Non-Invasive Screening and Consumer Health Monitoring

December 18
Last Trade: 8.34 4.24 103.41

Companies to leverage and collaborate on research and development, distribution, and regulatory expertise to accelerate global adoption of intelligent testing technologies Alliance positions INBS to enter the fast-growing consumer health market, broadening revenue opportunities beyond commercial screening NEW YORK, Dec. 18, 2025 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) (“INBS” or the “Company”), a...Read more


Treace Medical Secures Up to $175 Million in Debt Financing

December 18
Last Trade: 2.46 -0.02 -0.69

New 5-Year Agreement Provides Continued Financial Strength & Flexibility PONTE VEDRA, Fla., Dec. 18, 2025 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace” or the “Company”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities, today announced it has entered into a new five year $175 million senior secured loan arrangement with...Read more


Autonomix Medica Announces Abstract Selected for Poster Presentation at the 2026 American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium

December 18
Last Trade: 0.52 -0.06 -11.03

THE WOODLANDS, TX, Dec. 18, 2025 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company dedicated to advancing precision nerve-targeted treatments, today announced its abstract has been accepted for poster presentation at the 2026 ASCO Gastrointestinal Cancers Symposium, being held January 8-10, 2026 in San Francisco, CA. Details of the poster presentation are as...Read more


Butterfly Network to Present at the 44th Annual J.P. Morgan Healthcare Conference

December 18
Last Trade: 3.89 0.07 1.70

NEW YORK & BURLINGTON, Mass. / Dec 18, 2025 / Business Wire / Butterfly Network, Inc. (NYSE: BFLY) (“Butterfly”), a digital health company transforming care with handheld, whole-body ultrasound and intuitive software, today announced that it will participate in the 44th Annual J.P. Morgan Healthcare Conference taking place January 12-15, 2026 in San Francisco, California. Joseph DeVivo, President, Chief Executive Officer &...Read more


Envoy Medical Reaches Enrollment Milestone in Pivotal Clinical Study of Fully Implanted Acclaim(R) Cochlear Implant

December 18
Last Trade: 0.68 0.0046 0.68

Enrollment momentum accelerates as Company advances toward full enrollment White Bear Lake, Minnesota--(Newsfile Corp. - December 18, 2025) - Envoy Medical® Inc. (NASDAQ: COCH) ("Envoy Medical" or the "Company"), a hearing health company pioneering fully implanted hearing solutions, today announced that its pivotal clinical study for the investigational fully implanted Acclaim® cochlear implant has achieved yet another milestone by...Read more


Repligen to Present at J.P. Morgan 2026 Healthcare Conference

December 18
Last Trade: 165.84 -0.75 -0.45

WALTHAM, Mass., Dec. 18, 2025 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it will participate in the J.P. Morgan 2026 Healthcare Conference, being held January 12 – 15 in San Francisco. Olivier Loeillot, President and Chief Executive Officer, will present an overview of the company on Tuesday, January 13 at 2:15 p.m. PT. A live...Read more


Therma Bright Investee Company, InStatin Expands its Inhaled Statin Programs to include COPD (Chronic Obstructive Pulmonary Disease) as its Lead Indication.

December 18
Last Trade: 0.06 0.00 0.00

Includes Asthma in its strategic plans and Strengthens its Team in 2024-2025 Toronto, Ontario--(Newsfile Corp. - December 18, 2025) - Therma Bright Inc. (TSXV: THRM) (OTCQB: TBRIF) (FSE: JNX0) ("Therma" or the "Company"), a developer and investment partner specializing in advanced diagnostic and medical device technologies, is pleased to provide an update on Investee company, InStatin. InStatin, a biotechnology company developing...Read more


Edwards Lifesciences to Present at the 44th Annual J.P. Morgan Healthcare Conference

December 18
Last Trade: 86.01 -0.20 -0.23

IRVINE, Calif. / Dec 18, 2025 / Business Wire / Edwards Lifesciences Corporation (NYSE: EW) today announced it will participate in the J.P. Morgan Healthcare Conference on Monday, Jan. 12, 2026. Bernard Zovighian, chief executive officer, is scheduled to present at 11:15 a.m. PT. Scott Ullem, chief financial officer, will also participate in the conference. A live webcast of the presentation will be available on the Edwards Lifesciences...Read more


Perspective Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference

December 18
Last Trade: 2.74 -0.005 -0.18

SEATTLE, Dec. 18, 2025 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. ("Perspective" or the "Company") (NYSE AMERICAN: CATX), a radiopharmaceutical development company pioneering advanced treatments for cancers throughout the body, today announced that Thijs Spoor, Chief Executive Officer, will present at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco, CA, on Wednesday, January 14, 2026, at 2:15 p.m....Read more


Pulse Biosciences Announces FDA IDE Approval to Initiate its nPulse Cardiac Catheter Ablation System Study for the Treatment of Atrial Fibrillation

December 18
Last Trade: 13.75 0.00 0.00

HAYWARD, Calif. / Dec 18, 2025 / Business Wire / Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel nPulse™ technology using its proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™) energy, today announced that the U.S. Food and Drug Administration (FDA) has granted approval for the Company’s Investigational Device Exemption (IDE), allowing Pulse Biosciences to proceed with the initiation of its...Read more


Becton Dickinson and Penn Institute for Immunology and Immune Health Collaborate to Advance Immunotherapy through Flow Cytometry

December 18
Last Trade: 195.05 -0.59 -0.30

BD FACSDiscover™ A8 Cell Analyzer to Enable Investigation of 30+ Cellular Characteristics to Capture Key Biological Insights and Support Planned 1,000-Person Immune Profiling Study FRANKLIN LAKES, N.J., Dec. 18, 2025 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced a strategic collaboration with the Institute for Immunology and Immune Health (I3H) at the...Read more


Medline Announces Closing of Upsized Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares

December 18
Last Trade: 0 0.00 0.00

NORTHFIELD, Ill., Dec. 18, 2025 (GLOBE NEWSWIRE) -- Medline Inc. (Nasdaq: MDLN) (“Medline”) announced today that it has closed its upsized initial public offering of 248,439,654 shares of its Class A common stock at a public offering price of $29.00 per share, including the full exercise by the underwriters of their option to purchase up to an additional 32,405,172 shares of Class A common stock. Medline intends to use the proceeds (net...Read more


INVO Fertility Signs Definitive Purchase Agreement to Acquire Indiana-Based Fertility Clinic “Family Beginnings”

December 17
Last Trade: 2.04 0.00 0.00

Signing of definitive purchase agreement represents critical next step in completing previously announced acquisition SARASOTA, Fla. and INDIANAPOLIS, Dec. 17, 2025 (GLOBE NEWSWIRE) -- INVO Fertility, Inc. (Nasdaq: IVF) (“INVO” or the “Company”), a healthcare fertility company focused on the establishment, acquisition, and operation of fertility clinics and related businesses and technologies, today announced that it has signed a...Read more


Hyperfine Announces Regulatory Approval of the Swoop® System in India

December 17
Last Trade: 0.89 -0.02 -2.18

India's Central Drugs Standard Control Organization (CDSCO) has approved the Hyperfine Swoop system, opening a major global market. Commercial launch to begin early 2026. GUILFORD, Conn. / Dec 17, 2025 / Business Wire / Hyperfine, Inc. (Nasdaq: HYPR), the groundbreaking health technology company that has redefined brain imaging with the first FDA-cleared AI-powered portable MRI system for the brain—the Swoop® system—today announced the...Read more


NeuroPace Files PMA Supplement to FDA Seeking Expanded RNS® System Indication for Idiopathic Generalized Epilepsy

December 17
Last Trade: 15.39 -0.08 -0.52

Submission supported by positive preliminary 18-month NAUTILUS data in patients with drug-resistant idiopathic generalized epilepsy (IGE) and generalized tonic-clonic (GTC) seizures  MOUNTAIN VIEW, Calif. / Dec 17, 2025 / Business Wire / NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today announced that it has filed a Premarket Approval Supplement (PMA-S)...Read more


Lifeward Expands International Distribution of its ReWalk Personal Robotic Exoskeleton into Mexico, Thailand, and the United Arab Emirates

December 17
Last Trade: 0.58 0.02 2.69

Distribution agreement with Singapore-based Verita Neuro will provide patients the ReWalk Personal Exoskeleton as part of its multi-layered treatment modalities New delivery model for ReWalk will integrate in-patient training and rehabilitation to support clinical adoption in physical rehabilitation settings Over 7 million survivors of spinal cord injury (SCI) globally could potentially benefit from ReWalk, an estimated $1.75 billion...Read more


Beyond Air Signs New International LungFit PH® Distribution Agreements, Most Notably in Germany and Brazil

December 17
Last Trade: 0.70 0.0049 0.70

Distribution network coverage expanded to a total of 39 countries GARDEN CITY, N.Y., Dec. 17, 2025 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”), a commercial stage medical device and biopharmaceutical company focused on harnessing the power of nitric oxide (NO) to improve the lives of patients, today announced the recent signing of several key international distribution agreements for LungFit®...Read more


Bausch + Lomb Announces Two Board of Directors Appointments

December 17
Last Trade: 17.14 -0.02 -0.12

VAUGHAN, Ontario / Dec 17, 2025 / Business Wire / Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced that Eduardo C. Alfonso, MD, and Steven H. Collis have been appointed to its board of directors. The appointments are effective Jan. 1, 2026, and following changes announced in August 2025 the board will be comprised of 10 directors. “Eddie...Read more


Nyxoah Announces Commercial Launch of Genio® Breakthrough Therapy in the Netherlands

December 17
Last Trade: 4.70 0.05 1.08

First Genio implants successfully performed at OLVG West and Zuyderland hospitals Mont-Saint-Guibert, Belgium – December 17, 2025, 7:05am CET / 1:05am ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology company that develops breakthrough treatment alternatives for Obstructive Sleep Apnea (OSA) through neuromodulation, today announced the commercial launch of its Genio® system in the...Read more


Vivos Therapeutics Announces Grand Opening of Affiliated Sleep Center Near Detroit, Michigan

December 16
Last Trade: 2.05 -0.01 -0.49

Vivos Eyes High Growth Potential from Commercial Affiliation with Prominent Auburn Hills, Michigan Sleep Practice MISleep Solutions LITTLETON, Colo., Dec. 16, 2025 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or the “Company’’) (NASDAQ: VVOS), a leading medical device and healthcare services company focused on sleep related breathing disorders, including obstructive sleep apnea (OSA), is pleased to announce the grand opening...Read more


Hologic’s AI-Powered Mammography Technology Flagged a Third of Breast Cancer Cases Initially Interpreted as Negative in Study of 7,500 Screening Exams

December 16
Last Trade: 74.54 -0.02 -0.03

Retrospective analysis at top-tier medical facility highlights AI solution’s ability to help spot previously missed cancers and correctly localize suspicious areas on mammograms MARLBOROUGH, Mass. / Dec 16, 2025 / Business Wire / Hologic, Inc. (Nasdaq: HOLX), a leading medical technology company dedicated to improving women’s health, today announced new data that highlights how the company’s advanced AI-powered mammography solution can...Read more


Envoy Medical Secures New Australian Patent for Cochlear Implant Innovation Aimed at Enhancing Input Signal-to-Noise Ratio

December 16
Last Trade: 0.68 0.0046 0.68

Patent strengthens Company's global intellectual property portfolio and reinforces the Company's commitment to establishing and protecting competitive advantages White Bear Lake, Minnesota--(Newsfile Corp. - December 16, 2025) - Envoy Medical® Inc. (NASDAQ: COCH) ("Envoy Medical" or the "Company"), a hearing health company pioneering fully implanted hearing solutions, today announced the issuance of Australian Patent No. 2022229818,...Read more


Zimmer Biomet & OneStep Collaborate to Provide Enhanced Mobility Data to Patients and Surgeons to Help Improve Joint Procedure Recovery

December 16
Last Trade: 90.65 -0.14 -0.15

OneStep's Clinically Validated Mobility Intelligence Technology to Integrate into Zimmer Biomet's mymobility® Care Management Platform to Further Enhance Recovery Monitoring WARSAW, Ind., Dec. 16, 2025 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, and OneStep, the FDA-listed digital fall prevention and mobility intelligence platform, today announced an exclusive...Read more


Repligen Introduces Next-Generation Chromatography Resins to Advance New Modality Workflows

December 16
Last Trade: 165.84 -0.75 -0.45

WALTHAM, Mass., Dec. 16, 2025 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced the launch of three new high-performance chromatography resins: AVIPure® HiPer™ AAV9 and AVIPure® HiPer™ AAV8 affinity resins, along with HiPer™ QA anion exchange resin, expanding the company’s growing proteins portfolio and reinforcing its commitment to...Read more


Becton Dickinson Expands BD MAX™ System Menu with New IVDR-Certified VIASURE Assays in Partnership with Certest Biotec

December 15
Last Trade: 195.05 -0.59 -0.30

FRANKLIN LAKES, N.J., Dec. 15, 2025 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced the expansion of its respiratory and sexually transmitted infection (STI) diagnostics offerings in Europe following In Vitro Diagnostic Medical Device Regulation (IVDR) certification of two VIASURE assays developed by Certest Biotec for use on the BD MAX™ System. The addition of...Read more


GRAIL to Present at the 44th Annual J.P. Morgan Healthcare Conference

December 15
Last Trade: 84.26 -1.04 -1.22

MENLO PARK, Calif., Dec. 15, 2025 /PRNewswire/ -- GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today announced that company management will present at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco on Monday, Jan. 12 at 7:30 a.m. PT.  Live and replay webcasts may be accessed in the investor relations section of GRAIL's website at...Read more


HeartSciences Announces FDA 510(k) Submission for MyoVista® wavECG™ Device

December 15
Last Trade: 2.98 0.001 0.03

Southlake, TX, Dec. 15, 2025 (GLOBE NEWSWIRE) -- HeartSciences Inc.  (Nasdaq: HSCS; HSCSW) (“HeartSciences” or the “Company”), a healthcare information technology (“HIT”) company advancing the use of ECG/EKGs through the integration of artificial intelligence (“AI”), today announced it has submitted its MyoVista® wavECG™ device to the U.S. Food and Drug Administration (“FDA”) for 510(k) premarket clearance. The MyoVista wavECG...Read more


Hyperfine Announces FDA Clearance of the First Optive AI™ Software Update with Advanced Diffusion Imaging Capability, Focused on Enhancing Stroke Detection with the Swoop® System

December 15
Last Trade: 0.89 -0.02 -2.18

A new multi-direction DWI sequence, the latest Swoop® system software, and the first advancement in Hyperfine’s Optive AI™ software, delivers clearer, higher-quality images for stroke diagnosis, enhancing the value of the Swoop® system in acute neurological care. GUILFORD, Conn. / Dec 15, 2025 / Business Wire / Hyperfine, Inc. (Nasdaq: HYPR), the groundbreaking health technology company that has redefined brain imaging with the first...Read more


Quipt Home Medical Enters Into Definitive Agreement for Its Acquisition by Affiliates of Kingswood Capital Management and Forager Capital Management

December 15
Last Trade: 3.53 0.00 0.00

Quipt shareholders to receive US$3.65 per share in cash Transaction provides immediate liquidity and certainty of value to shareholders The per share purchase price represents a 162% premium to Quipt’s unaffected stock price on May 19, 2025, the last full trading day prior to the public disclosure of Forager’s $3.10 per share proposal, and a 54% premium to Quipt’s 30-day VWAP as of December 12, 2025 CINCINNATI, Dec. 15, 2025 (GLOBE...Read more


Quipt Home Medical Reports Fourth Quarter and Fiscal Year 2025 Financial Results

December 15
Last Trade: 3.53 0.00 0.00

CINCINNATI, Dec. 15, 2025 (GLOBE NEWSWIRE) -- Quipt Home Medical Corp. (the “Company”) (NASDAQ: QIPT; TSX:QIPT), a U.S.-based home medical equipment provider focused on end-to-end respiratory care, today announced its fourth quarter and fiscal year 2025 financial results and operational highlights. These results pertain to the three months and year ended September 30, 2025 and are reported in U.S. Dollars under GAAP. Financial...Read more


Inspira Technologies Announces $1.8 Million Registered Direct Offering Priced At-The-Market and Additional Equity Financing Agreement to Support Ongoing Commercial Execution

December 15
Last Trade: 0.92 0.0068 0.74

RA'ANANA, Israel, Dec. 15, 2025 (GLOBE NEWSWIRE) -- Inspira™ Technologies OXY B.H.N. Ltd. (NASDAQ: IINN, IINNW) ("Inspira," “Inspira Technologies,” or the "Company"), a pioneer in innovative life-support and diagnostic technologies, today announced that it has entered into a definitive agreement with YA II PN, Ltd. (“YA”) for a registered direct offering of its ordinary shares, and has also entered into a Standby Equity Purchase...Read more


HeartSciences Reports Fiscal Second Quarter 2026 Financial Results and Provides Business Update

December 15
Last Trade: 2.98 0.001 0.03

Southlake, TX, Dec. 15, 2025 (GLOBE NEWSWIRE) -- HeartSciences Inc. (Nasdaq: HSCS) (“HeartSciences” or the “Company”), a healthcare information technology (“HIT”) company focused on advancing electrocardiography (“ECG” or “EKG”) through the integration of artificial intelligence (“AI”), today reported financial results for its fiscal second quarter ended October 31, 2025 (“FQ2 2026”) and provided a business update. Second Quarter and...Read more


Theralase Technologies Commences Non-Brokered Private Placement and Termination of Previously Announced Financing

December 12
Last Trade: 0.16 0.00 0.00

Toronto, Ontario--(Newsfile Corp. - December 12, 2025) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a clinical stage pharmaceutical company pioneering light, radiation, sound and drug-activated therapeutics for the treatment of cancer, bacteria and viruses, has commenced a non-brokered private placement of units of the Company ("Units") to raise up to $CAN 2,000,000 ("Offering"). In...Read more


Kestra Medical Technologies Reports Second Quarter Fiscal 2026 Financial Results

December 11
Last Trade: 0 0.00 0.00

KIRKLAND, Wash., Dec. 11, 2025 (GLOBE NEWSWIRE) -- Kestra Medical Technologies, Ltd. (Nasdaq: KMTS), a wearable medical device and digital healthcare company, today reported financial results for the second quarter fiscal 2026, which ended October 31, 2025. Financial Highlights Generated revenue of $22.6 million in Q2 FY26, an increase of 53% compared to the prior year period. Expanded gross margin to 50.6% in Q2 FY26 compared to...Read more


Tivic Health Systems Acquires Ready-to-Scale cGMP Manufacturing and Development Assets to Accelerate Commercialization of Entolimod; Tivic Growth Backed By $90M+ Financing Package

December 11
Last Trade: 1.50 -0.05 -3.23

Acquisition creates additional near-term revenue opportunities from newly formed Contract Development and Manufacturing Organization (CDMO) subsidiary, Velocity Bioworks™ Financing led by 3i, LP includes $16M debt financing for the purchase of assets and up to $75M in preferred convertible equity available for therapeutics commercialization and corporate growth initiatives FREMONT, CA AND SAN ANTONIO, TX / ACCESS Newswire /...Read more


Baxter Presents Real-World Data at American Society of Health System Pharmacists Meeting Demonstrating Smart Infusion Pump Electronic Medical Record (EMR) Integration May Improve Patient Safety and Nursing Bedside Productivity

December 11
Last Trade: 19.27 -0.03 -0.16

Data shared in collaboration with The University of Texas Medical Branch, representing an analysis of more than one million intravenous (IV) infusions using Baxter’s Spectrum IQ large volume infusion pumps (LVP) Evaluation of pre- and post-smart pump EMR integration data showed a reduction in patient safety alerts, time spent to program an infusion and to resolve a pump alert Findings underscore the potential role of connected infusion...Read more


HeartSciences Announces Major Upgrade to User Features of MyoVista Insights Platform with Commercial Launch Version 1.1

December 11
Last Trade: 2.98 0.001 0.03

Version 1.1 Designed to Provide Best Usability of any ECG System Southlake, TX, Dec. 11, 2025 (GLOBE NEWSWIRE) -- HeartSciences Inc. (Nasdaq: HSCS; HSCSW) (“HeartSciences” or the “Company”), a healthcare information technology (“HIT”) company advancing the use of ECG/EKGs through the integration of artificial intelligence (“AI”), today announced the commercial release of MyoVista Insights™ version 1.1, a major update that is built...Read more


Egyptian Drug Authority Authorizes Biomerica’s Complete Screening Test Portfolio

December 11
Last Trade: 2.43 -0.02 -0.82

Authorization Covers Multiple Screening Tests for Cancer and Chronic Disease Risk Detection Portfolio includes tests for colorectal disease, breast self exam, prostate disease, kidney disease, and H. pylori infection Designed for early detection of conditions that are related to the most common cancers and chronic diseases Rapid, easy-to-use, and cost-effective screening for mass and individual use IRVINE, Calif., Dec. 11, 2025...Read more


Sign Up To Get Daily
Life Science News

Please review our Disclaimer and Privacy Policy before subscribing.

Medical Device Gainers

 
CompanyChangeLast Trade
Movano Health 5.07 163.02 $8.18
Intelligent Bio Solutions 4.24 103.41 $8.34
Establishment Labs 1.56 2.14 $74.48
TransMedics 1.23 1.01 $123.15
Owlet 0.41 2.56 $16.44
iRhythm Technologies 0.28 0.16 $178.85
TriSalus Life Sciences 0.22 3.31 $6.86
Penumbra 0.18 0.06 $314.45
Alphatec 0.16 0.77 $21.02
KORU Medical Systems 0.16 2.81 $5.85
Electromed 0.12 0.42 $28.95
LENSAR 0.10 0.86 $11.73
Anteris Technologies 0.10 1.97 $5.18
ENvue Medical 0.08 3.67 $2.27
NEXGEL 0.08 5.10 $1.65

Featured Stock

ClearPoint Neuro

ClearPoint Neuro is a global therapy-enabling platform company providing stereotactic navigation and delivery to the brain. Applications of our ClearPoint Neuro Navigation System include electrode lead placement, placement of catheters, and biopsy. The platform has FDA clearance and is...

CLICK TO LEARN MORE